175 related articles for article (PubMed ID: 38600316)
1. Combination p53 activation and BCL-x
Bell HL; Blair HJ; Jepson Gosling SJ; Galler M; Astley D; Moorman AV; Heidenreich O; Veal GJ; van Delft FW; Lunec J; Irving JAE
Leukemia; 2024 Apr; ():. PubMed ID: 38600316
[TBL] [Abstract][Full Text] [Related]
2. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL; Blair HJ; Singh M; Moorman AV; Heidenreich O; van Delft FW; Lunec J; Irving JAE
Cancer Cell Int; 2023 Sep; 23(1):202. PubMed ID: 37715172
[TBL] [Abstract][Full Text] [Related]
5. Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia.
Hohtari H; Kankainen M; Adnan-Awad S; Yadav B; Potdar S; Ianevski A; Dufva O; Heckman C; Sexl V; Kytölä S; Mustjoki S; Porkka K
Hemasphere; 2022 Mar; 6(3):e701. PubMed ID: 35233509
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
7. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
Khurana A; Shafer DA
Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
9. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
10. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA; Kerstjens M; Stam RW; Koster J; Goldsmith KC; Molenaar JJ; Dolman MEM
Mol Cancer Ther; 2021 Jun; 20(6):1161-1172. PubMed ID: 33850004
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
12. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H; Dufva O; Vähä-Koskela M; Leppä AM; Huuhtanen J; Vänttinen I; Nygren P; Klievink J; Bouhlal J; Pölönen P; Zhang Q; Adnan-Awad S; Mancebo-Pérez C; Saad J; Miettinen J; Javarappa KK; Aakko S; Ruokoranta T; Eldfors S; Heinäniemi M; Theilgaard-Mönch K; Wartiovaara-Kautto U; Keränen M; Porkka K; Konopleva M; Wennerberg K; Kontro M; Heckman CA; Mustjoki S
Blood; 2023 Mar; 141(13):1610-1625. PubMed ID: 36508699
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
14. The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857559
[TBL] [Abstract][Full Text] [Related]
15. Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines.
Lam LT; Zhang H; Xue J; Leverson JD; Bhathena A
Cancer Cell Int; 2015; 15(1):5. PubMed ID: 25685063
[TBL] [Abstract][Full Text] [Related]
16. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
17. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
